Is HIND or HRMY more undervalued in 2026?

CirclFi compares Vyome Holdings, Inc. (HIND) and Harmony Biosciences Holdings, I (HRMY) using 13 institutional-grade valuation models. HIND has a Quality of Company score of 5.1/10 while HRMY scores 10.0/10.

Which is a better buy — HIND or HRMY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HIND and HRMY valuations compare?

HIND at $2.35 and HRMY at $31.49 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HIND vs HRMY Valuation Comparison 2026 — Intrinsic Value Analysis

HIND

Biotechnology

Vyome Holdings, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$2.35

Last close

Models

12/13

Active

HRMY

Biotechnology

Harmony Biosciences Holdings, I

Quality

10.0

out of 10

Value Trap

SAFE

Price

$31.49

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	HIND Fair Value	HIND Upside	HRMY Fair Value	HRMY Upside
Bayesian DCF	Intrinsic	$0.84	-64.4%	$97.76	+210.5%
Earnings Power Value	Intrinsic	$0.88	-55.2%	$23.18	-26.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HIND vs HRMY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HIND vs HRMY — Which Stock Is More Undervalued?

HRMY scores higher with a 10.0/10 quality rating vs HIND's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vyome Holdings, Inc. (HIND) and Harmony Biosciences Holdings, I (HRMY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HIND currently trades at $2.35 with a QOC of 5.1/10, while HRMY trades at $31.49 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).